CIRCULATION OF HUMAN PAPILLOMAVIRUS (HPV) GENOTYPES IN WOMEN FROM CÓRDOBA, ARGENTINA, WITH SQUAMOUS INTRAEPITHELIAL LESIONS

Raul Fernando VENEZUELA, Ana Ximena KIGUEN, Maria Celia FRUTOS & Cecilia Gabriela CUFFINI

SUMMARY

Human papillomavirus (HPV) can induce a wide spectrum of squamous intraepithelial lesions (SIL) of varying severity. The aim of the present study was to establish the frequency of HPV infection and identify the genotypes circulating in women from Córdoba, Argentina, in relation to age and cytology. A total of 186 women, between 18 and 65 years old, with antecedents of SIL, underwent a pelvic examination and had cervical cells collected for cytology and HPV DNA detection. Ninety-six samples (51.6%) were positive for HPV detection, and sixty-three (65.6%) of them showed the presence of at least one HR-HPV. Low- and high-grade SIL showed significant association in patients younger than 35 years of age. We found 18 different genotypes, with a greater presence of HR-HPV. Genotypes 16 and 6 were the most frequent. Seven (7.3%) multiple infections, 85.7% of which had at least one HR-HPV, were detected.

The detection of a large number of different HPV genotypes is a warning sign. It is thus necessary to strengthen the monitoring of the circulation of high-risk genotypes, currently less prevalent in intraepithelial lesions, as a control measure for the possible impact of the implementation of vaccines against genotypes 16 and 18.

KEYWORDS: HPV; Squamous intraepithelial lesions; Cervix; Genotypes, Argentina.

INTRODUCTION

Human Papillomavirus (HPV) can induce a wide spectrum of squamous intraepithelial lesions of varying severity. The prevalence of HPV genital infection, which is the most common sexually transmitted infection worldwide, depends on the woman’s age and the method of detection. Numerous studies have reported that certain types of HPV are the main cause of cervical cancer. More than 40 genotypes have been identified in the anogenital tract. Depending on their association with low/high-grade squamous intraepithelial lesions or invasive carcinomas, they can be grouped into low-risk (LR-HPV), such as HPV 6 and 11, and high-risk HPV (HR-HPV), such as HPV 16, 18, 31, and 33.

The pathogenesis of cervical cancer begins as a slow process that disrupts the differentiation of the cervical squamous epithelium, causing changes in its structure and physiology.

Cervical cell dysplasia, which is evidenced by alterations in the shape, size and organization of the epithelium, is caused as a result of infection with HPV.

By means of the Bethesda System, these lesions may be classified as: atypical squamous cells of undetermined significance (ASCUS), low-grade squamous intraepithelial lesions (LSIL), high-grade squamous intraepithelial lesions (HSIL) or Squamous Cell Carcinoma (SCC).

The knowledge of HPV genotypes in our female population is important for establishing strategies to prevent SCC and control squamous intraepithelial lesions, including the molecular diagnosis of the virus and vaccination. Thus, considering the recent inclusion of anti-HPV vaccines in the National Vaccination Calendar, the monitoring of circulating genotypes should be sustained over time, since the possible existence of mechanisms of immune pressure would result in a decreased circulation of the genotypes listed in the vaccines and the consequent increase in the frequency of detection of those not included in the formulation.

The goal of the present study was to establish the frequency of HPV infection and identify the genotypes circulating in women in the city of Córdoba, Argentina, in relation to age and cytology.

MATERIALS AND METHODS

A total of 186 women with antecedents of squamous intraepithelial lesions who attended private clinics and public health centers in Córdoba, Argentina, between May 2008 and May 2010 were invited to participate in a cross-sectional study on cervical HPV infection. At the beginning of the study, participants answered a questionnaire and signed a written consent form, in accordance with the Ethics Committee of the School of
Medical Sciences of the University of Córdoba. Participants were then subjected to a pelvic examination for the collection of cervical cells for cytology and HPV-DNA detection.

The samples were collected in 500 μL phosphate-buffered saline (PBS). DNA was extracted using the commercial AccuPrep Genomic DNA Extraction Kit (Bioneer Inc., CA, USA), in accordance with the manufacturer’s instructions.

A 450-bp segment, corresponding to the L1 region of the viral genome, was amplified by PCR, using the degenerate primers MY09 and MY11 (Integrated DNA Technology - USA). The product was detected by electrophoresis in agarose gel at 1.5% using a U.V. transilluminator. The β-globin gene was used as a DNA preservation marker. Negative samples were considered inadequate.

HPV-DNA positive samples were typed by Restriction Fragment Length Polymorphism (RFLP) according to BERNARD et al., 1994. Briefly, aliquots of the PCR products obtained using the degenerate consensus primers MY09–MY11, targeting a region of approximately 450 bp in length in the L1 ORF of the viral genome, were mixed with seven different restriction enzymes (Bam HI, Hae III, Dde I, Pst I, Hind II, Sau III, and Rsa I) in separate reactions. The digestion products were separated by electrophoresis in 3% agarose gel and the pattern obtained was compared with published data.

Statistical analysis was carried out with InfoStat version 2011, with a significance level of 5% [95% CI].

In order to estimate the probabilities of occurrence, we calculated the frequencies for the different genotypes, ages and cytological characteristics.

Chi-square (χ2) tests for independence were conducted to determine the association between different age groups, cytological characteristics, HPV genotype and risk. At the same time, logistic regressions were performed to determine association between age, type of lesion (LSIL/HSIL) and genotype. For the latter, we worked with genotypes 6, 11, 16 and 18.

RESULTS

The age of the patients ranged between 18 and 65 years old (mean age 31.13 years) and the distribution by age was as follows: < 25 years (x 22.1 SD 1.79) = 35 (18.8%), 25-34 years (x 29.5 SD 2.76) = 96 (51.6), 35-44 years (x 38.9 SD 2.89) = 28 (15.1%) and ≥ 45 years (x 48.7 SD 5.71) = 11 (5.9%). Age information was not available for sixteen of the samples (8.6%). These samples were thus excluded from the age analysis.

The Papanicolaou smears were stained and interpreted locally by a team of cytopathologists and the results were classified according to the Bethesda System. LSIL was diagnosed in 120 women (64.5%), HSIL in 42 (22.6%), ASCUS in 16 (8.6%), and SCC in one (0.5%). Seven samples (3.8%) were normal.

All of the samples showed gene amplification for the beta-globin.

Ninety-six samples (51.6%) were positive for HPV detection, and sixty-three (65.6%) of them (i.e. 33.9% of all samples) showed the presence of at least one HR-HPV.

Table 1 shows the detection of HPV (HR-HPV and LR-HPV) in function of age, compared with the cytological classification.

Although the overall analysis did not show predominance of any of the cytological classifications by age group (χ2 = 17.9, p = 0.3276), in the analysis of independence between the age group and the type of lesion (HSIL and LSIL), we found a significant association with women under 35 years (χ2 = 4.9, p = 0.026 OR = 0.30, 0.10 to 0.87).

Table 1

<table>
<thead>
<tr>
<th>Age</th>
<th>ASCUS</th>
<th>HR-HPV</th>
<th>LR-HPV</th>
<th>LSIL</th>
<th>HR-HPV</th>
<th>LR-HPV</th>
<th>HSIL</th>
<th>HR-HPV</th>
<th>LR-HPV</th>
<th>TOTAL</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt; 25 n°</td>
<td>2</td>
<td>2</td>
<td></td>
<td>23</td>
<td>11</td>
<td>3</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>35</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
<td></td>
<td>21</td>
<td>17</td>
<td>3</td>
<td>27</td>
<td>21</td>
<td>2</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
<td></td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>2</td>
<td>2</td>
<td></td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>25-34 n°</td>
<td>7</td>
<td>3</td>
<td></td>
<td>57</td>
<td>17</td>
<td>6</td>
<td>23</td>
<td>21</td>
<td>2</td>
<td>96</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3</td>
<td></td>
<td>21</td>
<td>2</td>
<td>2</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3</td>
<td></td>
<td>6</td>
<td>2</td>
<td>2</td>
<td>1</td>
<td>2</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3</td>
<td></td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>12</td>
</tr>
<tr>
<td>35-44 n°</td>
<td>3</td>
<td>3</td>
<td></td>
<td>28</td>
<td>10</td>
<td>11</td>
<td>23</td>
<td>21</td>
<td>2</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3</td>
<td></td>
<td>10</td>
<td>11</td>
<td>11</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3</td>
<td></td>
<td>11</td>
<td>7</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>3</td>
<td>3</td>
<td></td>
<td>6</td>
<td>6</td>
<td>5</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>63</td>
</tr>
<tr>
<td>≥45 n°</td>
<td>1</td>
<td>1</td>
<td></td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>16</td>
</tr>
<tr>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>16</td>
</tr>
<tr>
<td>WITHOUT AGE</td>
<td>6</td>
<td>3</td>
<td></td>
<td>23</td>
<td>12</td>
<td>11</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>3</td>
<td></td>
<td>12</td>
<td>11</td>
<td>11</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>3</td>
<td></td>
<td>11</td>
<td>7</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>63</td>
</tr>
<tr>
<td></td>
<td>6</td>
<td>3</td>
<td></td>
<td>7</td>
<td>6</td>
<td>5</td>
<td>2</td>
<td>2</td>
<td>2</td>
<td>63</td>
</tr>
<tr>
<td>TOTAL n°</td>
<td>16</td>
<td>9</td>
<td></td>
<td>35</td>
<td>21</td>
<td>21</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>9</td>
<td></td>
<td>35</td>
<td>21</td>
<td>21</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>9</td>
<td></td>
<td>35</td>
<td>21</td>
<td>21</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>86</td>
</tr>
<tr>
<td></td>
<td>16</td>
<td>9</td>
<td></td>
<td>35</td>
<td>21</td>
<td>21</td>
<td>7</td>
<td>2</td>
<td>2</td>
<td>86</td>
</tr>
</tbody>
</table>

The multiple infections that had at least one HR-HPV were considered to be HR-HPV because of their clinical importance. Data not included in the table: Normal, 2 patients, < 25, 2 patients, 25-34, 1 patient, 35-44, 1 patient, ≥ 45 and Without Age, 1 that was LR-HPV, SCC: 1 patient < 25 HR-HPV.
The HSIL lesion type had the highest detection of HPV (71.4%) and frequency of HR-HPV (86.7%). However, the distribution of HR-HPV did not show a statistically significant association with the type of lesion ($\chi^2 = 2.7, p = 0.0995$ OR = 0.43, 0.16, 1.16). In spite of this, except for the group < 25 years old, the detection rate of HR-HPV in HSIL was higher than 90%.

In addition, HPV detection exceeded 50% in all age groups, except for the 35–44 year old group; in the group < 25 years old we detected the largest percentage of HR-HPV (76.2%), most of which (78.6%) were detected in LSIL.

Table 2 shows the distribution of genotypes according to the cytological classification. The most prevalent genotypes were 16 and 6. Together, these two genotypes reached 50% of the total (52/104, including multiple infections). Both were identified in all cytological classifications, except for genotype 6 in SCC and 16 in normal.

Genotype 16 was the most prevalent in SCC and HSIL, whereas genotype 6 was the most prevalent in normal samples as well as in ASCUS and LSIL.

The second most prevalent LR-HPV was genotype 11 (8.3%), which was detected only in ASCUS and LSIL, whereas the second most prevalent HR-HPV were genotypes 18, 52 and 58 (6.2% each), which were found in LSIL and HSIL, with a higher percentage in the latter.

The four most frequent genotypes in HSIL were 16, 52, 18 and 58, whereas the most frequent in LSIL were 6, 16, 11 and 31.

In the logistic regression analysis for lesion type, age and genotype, HPV 16, 11 and 18 were present in all age groups and lesion types, without statistical association. In contrast, genotype 6 showed association with LSIL ($\beta = -1.65, p value = 0.0417, OR = 0.19, 0.04-0.94$), but such association was not observed with the different ages (Table 3).

RFLP analysis detected the presence of seven (7.3%) multiple infections, 85.7% of which had at least one HR-HPV, being genotype 16 the most frequent one. The distribution of these infections according to the lesion was: LSIL 57.1%, HSIL 28.6% and ASCUS 14.3%, but the frequencies of multiple infections vs. lesions did not show significant differences ($\chi^2 = 3.75, p value = 0.4409$).

Six of these multiple infections (85.7%) were observed in women under 35 years old, more frequently in the 25-34 year old group (57.1%) (data not shown).
that, in agreement with what was previously reported\textsuperscript{15,31}, HPV 16 can be found in HSIL and LSIL. However, in our population, genotype 16 was found mostly in HSIL.

In agreement with the findings of other authors\textsuperscript{21}, HR-HPV 16, 18, 52 and 58 were most frequently detected in HSIL. We also found that the only LR-HPV genotypes found in HSIL were 6 and 54, the latter of which was found in multiple infections with HPV 6.

Among the genotypes not present in the development of vaccines, the most frequently detected were HPV 52 and HPV 58 (Table 2). These were more common in HSIL and observed in the 25-34 age group (data not shown).

Some prevalence studies have indicated that the DNA of HPV 52 is present in approximately 2\% of all cases of cervical squamous intraepithelial lesions\textsuperscript{26,29} and that the presence of HPV 58 for these lesions ranges from 6\% to 20\%, which is the range within which these genotypes were detected in our work\textsuperscript{13,24,25,26}.

The detection of multiple infections was lower than that in other regions, and at least one HR-HPV was detected in most multiple infections\textsuperscript{22}. Some studies have reported a close association between multiple infections and the increase in the severity of the lesion\textsuperscript{10,19}. However, in agreement with other studies, most of the multiple infections in our work were detected in LSIL (57.1\%). This could be due to the fact that in high-grade lesions, the viral DNA is integrated into the host’s genome, which leads to partial loss of the region of the L1 gene, to which the amplification by the MY09/11 primer set is directed\textsuperscript{15,32}.

Another interesting aspect of the presence of these infections is the generation of an environment that favors potential recombination, which may have a major impact on pharmacogenomics and primary prevention with the implementation of existing vaccines\textsuperscript{1}.

It is noteworthy that the variety of HR-HPV is about twice that of LR-HPV (11 vs. 7), and, as shown in Fig. 1, although immunization with existing vaccines would cover more than 50\% of infections, a high percentage (45.3\%) of HR-HPV infections would not be prevented by these vaccines. Although the cross-protection data are encouraging\textsuperscript{16,30}, the titers of the neutralizing antibodies for the genotypes not included in the formulation are about ten times lower than those for the genotypes that are included. This generates uncertainty about whether they will disappear more rapidly than the specific antibodies. It has also been reported that the protection against HPV 52 and HPV 58 (two of the four most frequent HR-HPV in our study) is not significant. These data have led some authors to infer that the cross-protection seems to be limited\textsuperscript{27,30}.

The distribution of HPV among different populations is not homogeneous, and the interaction of human relations leads to viral dynamics that could alter the relative risk of each lesion in the population, especially when prevalence of HR-HPV is high\textsuperscript{14}.

The information provided in the present study, which is the first to be carried out in Córdoba, Argentina, is important for the prevention of HPV, and highlights the importance of routine gynecological controls in women younger than 35 years of age, since this age group was found to be associated with LSIL and HSIL. Another important finding is that
El papilomavirus humano (human papilloma, HPV) induce un amplio espectro de lesiones intraepiteliales escamosas (SIL) de variada severidad. Objetivo: conocer la frecuencia de infección por HPV y determinar los genotipos circulantes en mujeres de la ciudad de Córdoba, Argentina, en relación con la edad y la citología. Se realizó citología y detección de ADN-HPV en células cervicales de 186 mujeres de 18 a 65 años con antecedentes de SIL. Noventa y seis (51.6%) fueron positivas para la detección del HPV, de las cuales, en 63 (65.6%) se detectó la presencia de al menos, un HPV de Alto Riesgo (HR-HPV). Las SIL de alto grado (HSIL) y de bajo grado (LSIL) se asociaron a pacientes menores de 35 años. Se hallaron 18 genotipos diferentes, con mayor presencia de HR-HPV. HPV 16 y 6 fueron más frecuentes y se detectaron 7 (7.3%) infecciones múltiples, 85.7% de éstas presentaron al menos un HR-HPV. La detección de un alto número de diferentes genotipos es una señal de alerta. Por tanto, es necesario fortalecer la vigilancia de los HR-HPV, actualmente menos frecuentes en las SIL, como medida de control del impacto que tendrá la implementación de las vacunas contra HPV 16 y 18.

**ACKNOWLEDGMENT**

This work was supported by grants from the Ministerio de Ciencia y Tecnología (MINCyT) PIO 170/2011.

**REFERENCES**


Received: 5 August 2011
Accepted: 10 November 2011